The burgeoning landscape of novel treatments for weight management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a alike https://bookmarkvids.com/story22216969/retatrutide-vs-tirzepatide-a-comparative-analysis